bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 3. Induction of gene expression via XREs by NK150460 or aryl hydrocarbon receptor agonists.
Supplementary Video 4 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Supporting Video S4. Video S3 with MR, without CT. Horizontal PET(red)/MR(grey) projection showing dynamic, CED delivery of [18F]-1. PET is overexposed to emphasize gastrointestinal clearance. Major quantities of [18F]-1 are delivered to glioma. Time on video is vs. PET scan start. CED was started 17 min into the PET scan. (Video of Fig.4Aii and iii)
Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Authors: Huang Xinqiang , Magnus Jill , Kaimal Vivek , Karmali Priya , Li Jian , Walls Marlena , Prudente Rene , Sung Eric , Sorourian Mehran , Lee Robin , Davis Scott , Yang Xia , Estrella Heather , Lee Edmund C. , Chau B. Nelson , Pavlicek Adam , Zabludoff Sonya
Published: April 2023

MetaCoreTM schematic of the TGF-β signaling pathway showing genes regulated by miR-17 TuD in Hep3B (1) and HepG2 (2).
Supplementary Figure 3 from Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy
Authors: Kermer Vanessa , Hornig Nora , Harder Markus , Bondarieva Anastasiia , Kontermann Roland E. , Müller Dafne
Published: April 2023

PDF - 49KB, Comparison of the cytokine activity of RD_IL-15_scFv and scFv_RD_IL-15.
Supplementary Figure 1 from Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy
Authors: Kermer Vanessa , Hornig Nora , Harder Markus , Bondarieva Anastasiia , Kontermann Roland E. , Müller Dafne
Published: April 2023

PDF - 170KB, Combined effect of IL-15 and scFv_4-1BBL on the proliferation (A) and IFN-γ release (B) of activated T cells and PBMCs, respectively.
Supplementary Table S4 from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Authors: Wilsbacher Julie L. , Cheng Min , Cheng Dong , Trammell Samuel A.J. , Shi Yan , Guo Jun , Koeniger Stormy L. , Kovar Peter J. , He Yupeng , Selvaraju Sujatha , Heyman H. Robin , Sorensen Bryan K. , Clark Richard F. , Hansen T. Matthew , Longenecker Kenton L. , Raich Diana , Korepanova Alla V. , Cepa Steven , Towne Danli L. , Abraham Vivek C. , Tang Hua , Richardson Paul L. , McLoughlin Shaun M. , Badagnani Ilaria , Curtin Michael L. , Michaelides Michael R. , Maag David , Buchanan F. Gregory , Chiang Gary G. , Gao Wenqing , Rosenberg Saul H. , Brenner Charles , Tse Chris
Published: April 2023

Structures and PC3 viability IC50 data for compounds in Figure 2.
Supplementary Table 3 from Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma
Authors: Ohata Yoshiteru , Shimada Shu , Akiyama Yoshimitsu , Mogushi Kaoru , Nakao Keisuke , Matsumura Satoshi , Aihara Arihiro , Mitsunori Yusuke , Ban Daisuke , Ochiai Takanori , Kudo Atsushi , Arii Shigeki , Tanabe Minoru , Tanaka Shinji
Published: April 2023

Clinicopathological characteristics of patients with Tβ4-high and -low HCC
Supplementary Figure 2 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Authors: Zhou Yan , Zhao Conghui , Gery Sigal , Braunstein Glenn D. , Okamoto Ryoko , Alvarez Rocio , Miles Steven A. , Doan Ngan B. , Said Jonathan W. , Gu Jiang , Phillip Koeffler H.
Published: April 2023

PDF - 3009KB, Effect of Tivantinib and Crizotinib on cell growth and c-MET phosphorylation of MDA-MB-231 and HT29 cells.
Supplementary Materials and Methods and Figure Legends from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Supplementary Materials and Methods and Figure Legends
Supplementary Figure S6 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells.
Supplementary Figure 1A from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Authors: Kobayashi Yoshihisa , Azuma Koichi , Nagai Hiroki , Kim Young Hak , Togashi Yosuke , Sesumi Yuichi , Chiba Masato , Shimoji Masaki , Sato Katsuaki , Tomizawa Kenji , Takemoto Toshiki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

Growth inhibitory curves of Ba/F3 cells expressing EGFR Del18
Supplementary Figures S1, S2 and S3 from Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
Authors: Gimenez-Xavier Pol , Pros Eva , Bonastre Ester , Moran Sebastian , Aza Ana , Graña Osvaldo , Gomez-Lopez Gonzalo , Derdak Sophia , Dabad Marc , Esteve-Codina Anna , Hernandez Mora Jose R. , Salinas-Chaparro Diana , Esteller Manel , Pisano David , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Figure S1. Cell viability and colony formation assays of the indicated cell lines. Supplementary Figure S2. Multidimensional scaling plots Supplementary Figure S3. Cell viability assays and western blots
Supplemental Figure 1 from miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases
Authors: Yang Yuanzheng , Huang Gangxiong , Zhou Zhichao , Fewell Jason G. , Kleinerman Eugenie S.
Published: April 2023

Over-expression of miR-20a decreases Fas expression in OS cells.
Supplementary Tables 1-5 and figures 1-3 from Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
Authors: Floc'h Nicolas , Ashton Susan , Ferguson Douglas , Taylor Paula , Carnevalli Larissa S. , Hughes Adina M. , Harris Emily , Hattersley Maureen , Wen Shenghua , Curtis Nicola J. , Pilling James E. , Young Lucy A. , Maratea Kim , Pease Elizabeth J. , Barry Simon T.
Published: April 2023

Supplementary Table 1. Mass Spectrometer and UPLC system parameters, Supplementary Table 2. Optimization parameters for mass spectrometry analysis, Supplementary Table 3. Estimated mouse PK model parameter values for AZD2811, Supplementary Table 4. Summary table of the pIC50 and nuclear area, Supplementary Table 5: PK parameters summary, Supplementary Figure 1. Representative bioluminescent images of the disseminated U2932Luc2 DLBCL xenograft model in vivo taken at day 18 post treatment initiation, Supplementary Figure 2. 96h post treatment, AZD2811 nanoparticle treatment reduces pHH3 levels with no evidence of polyploidy in the OCI-LY19 xenograft model in vivo, Supplementary Figure 3. In SCID mice AZD2811 nanoparticle is well tolerated at the different doses and schedules explored
Tables S6-S7 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S6: Differentially expressed transcripts in PRPF8-KD cells;Table S7: Differentially expressed transcripts in PRPF38A-KD cells
Tables S2_S10_S14 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S2: Top siRNA screen hits; Table S10: Summary of validated PRPF8-sensitive transcripts across multiple cell lines; Table S14: BE dosing schedules
Table S1 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S1: siRNA screening data
Supplementary Figures S1-S4 from Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer
Authors: Aboubakar Nana Frank , Lecocq Marylène , Ladjemi Maha Zohra , Detry Bruno , Dupasquier Sébastien , Feron Olivier , Massion Pierre P. , Sibille Yves , Pilette Charles , Ocak Sebahat
Published: April 2023

Supplementary Figure S1: Western blot densitometric quantifications. Supplementary Figure S2: FAK Inhibitor 14 (Inh14) and PF-562,271 (PF-271)'s effects on FAK expression/activity, cell proliferation, and apoptosis in NCI-H446 SCLC cell lines. Supplementary Figure S3: PF-573,228 (PF-228)'s effects on FAK expression/activity, cell proliferation, and apoptosis in NCI-H82 SCLC cell lines transduced with FAK shRNA. Supplementary Figure S4: phospho-Paxillin expression in NCI-H446 SCLC cell line where FAK has been inhibited with pharmacological and genetic methods.
Supplemental figure 4 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

GSEA with Hallmark gene sets performed on transcriptional changes in HT1197 cells treated with panobinostat for 48 hours. A. Top 6 downregulated GSEA signatures B. Top 6 upregulated GSEA signatures C. GSEA HT1197 vs UMUC3 ( comparison of transcriptome of untreated samples reveals significantly greater presence of the E2F target gene signature in HT1197 cells).
Supplementary Figure 2 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

The ROC curves created to determine the cutoff score for over expression of PRL-3 in CRC and the qRT-PCR original data for 7 gene
Supplementary Figure 1 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

Knockdown the PRL-3 gene in HT29 cells
Supplementary Figure S6 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S6. Effect of RI phosphorylation on its affinity for ANG. A and B, Images showing the proximity of a phosphoryl group on Ser289 of RI (panel A) or Ser405 of RI (panel B) to key residues of ANG in the RIÂ·ANG complex. RI is depicted as a gray ribbon; ANG is depicted as a green ribbon. Ser87 is phosphorylated in ANG(1). A phosphoryl group was installed computationally on OÎ³ of the two serine residues of RI. The image was made with PDB entry 1a4y and the program PyMOL.
Table S3 from Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin
Authors: Zhang Yong , Dong Yinhui , Melkus Michael W. , Yin Shutao , Tang Su-Ni , Jiang Peixin , Pramanik Kartick , Wu Wei , Kim Sangyub , Ye Min , Hu Hongbo , Lu Junxuan , Jiang Cheng
Published: April 2023

Table S3 shows effect of bufalin on cyclins (CCN) and mini-chromosome maintenance (MCM) genes in LNCaP cells exposed for 24 h. Expressed relative to control set as unity.
Supplementary Figure S2 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S2. Expression and purification of biotinylated RI. Biotinylated RI was produced in HEK293T cells. Plasmids that direct the expression of BAP-RI and BirA were transfected transiently into cells. A, Immunoblot showing that a 1:1 ratio of Lipofectamine 3000 to DNA plasmids yielded more biotinylated RI than did a 1:2 or 2:1 ratio. B, Immunoblot showing that RI production was greater after transfection for 48 h than for 24 or 72 h. C, SDS-PAGE gel showing that RI production was greater after transfection for 48 h than for 24 or 72 h. D, SDS-PAGE gel showing human-derived RI (which is biotinylated) that was purified by chromatography using monomeric avidin agarose and an RNase A-affinity column. Elution of human-derived RI from an RNase A-affinity column required 3.5 M NaCl, whereas elution of E. coli-derived RI required 3.0 M NaCl. E, Autoradiogram of a polyacrylamide gel showing that E. coli-derived RI is phosphorylated upon incubation with a HEK293T cell lysate and [Î³-32P]ATP. Human angiogenin, which is known to be phosphorylated (Hoang TT, Raines RT. Molecular basis for the autonomous promotion of cell proliferation by angiogenin. Nucleic Acids Res 2017;45:818-31), serves as a positive control.
Figure S8 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of ceramide nanoliposomes on cell motility in multiple ovarian cancer cell lines
Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition
Authors: Ma Shaolin , Pradeep Sunila , Villar-Prados Alejandro , Wen Yunfei , Bayraktar Emine , Mangala Lingegowda S. , Kim Mark Seungwook , Wu Sherry Y. , Hu Wei , Rodriguez-Aguayo Cristian , Leuschner Carola , Liang Xiaoyan , Ram Prahlad T. , Schlacher Katharina , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Materials. Chemical structure and amino acid sequence of EP-100. Supplementary Figure S1. Expression and localization of GnRH-R in ovarian cancer cells. Supplementary Figure S2. The effects of GnRH-R loss on the cytotoxicity of EP-100. Supplementary Figure S3. Effects of doxorubicin, paclitaxel, olaparib, topotecan, and cisplatin on the viability of ovarian cancer cells. Supplementary Figure S4. Combined effects of EP-100 with doxorubicin, paclitaxel, topotecan and cisplatin on ovarian cancer cells. Supplementary Figure S5. Protein expressions as detected by RPPA assay. Supplementary Figure S6. The combined effect of treatment with EP-100 and olaparib in a subcutaneous mice model. Supplementary Figure S7 (related to Supplementary Figure S1 and Supplementary Figure S2). The original figures of the Western Blotting bands for GnRH-R expression. Supplementary Figure S8 (related to Figure 4A). Representative comets from comet assays. Supplementary Figure S9 (related to Figure 4C and D). Representative images from immunofluorescence assay.
Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition
Authors: Ma Shaolin , Pradeep Sunila , Villar-Prados Alejandro , Wen Yunfei , Bayraktar Emine , Mangala Lingegowda S. , Kim Mark Seungwook , Wu Sherry Y. , Hu Wei , Rodriguez-Aguayo Cristian , Leuschner Carola , Liang Xiaoyan , Ram Prahlad T. , Schlacher Katharina , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Table S2. The IC50s of EP-100 against shRNA transfected ovarian cancer cells
Supplementary Data from Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog
Authors: Elsaid Mohamed Y. , Shahi Ankita , Wang Albert R. , Baiu Dana C. , Li Chunrong , Werner Lauryn R. , Singhal Sorabh , Hall Lance T. , Weichert Jamey P. , Armstrong Eric A. , Bednarz Bryan P. , Harari Paul M. , Iyer Gopal , Otto Mario
Published: April 2023

Supplementary Table 1. List of Antibodies used for Western and IHC. Supplementary Table 2. Plating efficiency (clonogenic assay). Supplementary Table 3. Statistical analysis of tumor growth rates in xenograft experiments (linear mixed effects model with animal-specific random effects). Supplementary Figure 1. CLR127 effect on cell viability (MTT Assay). Supplementary Figure 2. Effect of CLR127 (CLR) and radiation on DNA damage repair by western blot. Supplementary Figure 3. Tumor growth rates of flank xenografts after treatment with radiation, CLR127 or combination therapy.
Figure S2 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

The accumulation of phospho-ATM, γ-H2AFX and cleaved PARP in Raji compared to that in Raji/253R cells exposed to APTO-253 for 24 h.
Figure S3 from The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth
Authors: Wang Yuhua , Pandey Ram Naresh , Riffle Stephen , Chintala Hemabindu , Wikenheiser-Brokamp Kathryn A. , Hegde Rashmi S.
Published: April 2023

BZ cytotoxicity assay
Figure S2 from The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth
Authors: Wang Yuhua , Pandey Ram Naresh , Riffle Stephen , Chintala Hemabindu , Wikenheiser-Brokamp Kathryn A. , Hegde Rashmi S.
Published: April 2023

Loss of EYA3 in LLC cells leads to reduced tumor growth.
Figure S2 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

E2 suppressed the expression of PPARγ target gene ACOX3 in three breast cancer cell lines. MCF-7 cells were transferred from phenol red containing medium to E2-free medium for 3 days. Next, (A) MCF-7, (B) MCF-7:5C, and (C) MCF-7:2A cells were seeded in six-well plates. After 24 hours, cells were treated with a vehicle control (0.1% EtOH) or E2 (1 nM) for 24, 48, 72 hours. Cells were then harvested in TRIzol reagent. ACOX3 expression levels were quantitated using RT-PCR. *P<0.05 compared with control; **P<0.001 compared with control.
Figure S1 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Expression of PPARγ and its function in breast cancer cell lines. A, MCF-7 cells were transferred from phenol red containing medium to E2-free medium for 3 days. Cells were then harvested similarly to that performed for MCF-7:5C and MCF-7:2A cells in TRIzol reagent. PPARγ expression levels were quantitated using RT-PCR. **P<0.001 compared with control. B, MCF-7 cells were seeded in 24-well plates. Then, cells were treated with a vehicle control (0.1% DMSO) or different concentrations (from 50 nM to 5µM) of T0070907 for 7 days. Cells were harvested for DNA proliferation assay. *P<0.05, **P<0.001. C, MCF-7:5C and MCF-7:2A cells were seeded in 24-well plates. Then, cells were treated with a vehicle control (0.1% DMSO) or T0070907 (5µM) for 7 days. Cells were harvested for DNA proliferation assay. **P<0.001. D, Growth response to T0070907 in T47D-derived cells. T47D cells were transferred to E2-free medium for 3 days. Then, T47D and T47D:C42 were treated with a vehicle control (0.1% DMSO) or T0070907 (5µM) in 24-well plates for 7 days. Cells were then harvested for DNA proliferation assay. *P<0.05, **P<0.001. E, ZR-75-1 cells were transferred from phenol red containing medium to E2-free medium for 3 days and seeded in a 24-well plate. After 24 hours, cells were treated with a vehicle control (0.1% DMSO) or T0070907 (5µM) for 7 days. Cells were then harvested for use in a DNA proliferation assay. **P<0.001 compared with control. F, BT-474 were seeded in 24-well plates. Then, cells were treated with a vehicle control (0.1% DMSO) or different concentrations (from 1 µM to 10µM) of T0070907 for 7 days. Cells were harvested for DNA proliferation assay. **P<0.001. G, Sk-Br-3 were seeded in 24-well plates. Then, cells were treated with a vehicle control (0.1% DMSO) or different concentrations (from 1 µM to 10µM) of T0070907 for 7 days. Cells were harvested for DNA proliferation assay. *P<0.05, **P<0.001. H, MDA-MB-231 cells were seeded in 24-well plates. Then, cells were treated with a vehicle control (0.1% DMSO) or different concentrations (from 2 µM to 10µM) of T0070907 for 7 days. Cells were harvested for DNA proliferation assay.
Supplementary Fig 3 from Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
Authors: Gupta Nehal , Srivastava Sanjay K.
Published: April 2023

Supplementary figure S3 shows the effect of the combination of β-catenin inhibitor, IWP-2 and atovaquone in MCF-7HH cells by western blotting.
Supplementary Materials from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Supplementary Materials
Supplementary Table 2 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

A Bio-Layer Interferometry (BLI)-based method (Forte Bio Octet Red 96) for determining binding rate constants (kon, koff, KD) was utilized to provide kinetic data on the interaction between the monoclonal antibodies (human IgG1 reference standard and TSR-033) and human CD16a
Table S7 from APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Authors: Local Andrea , Zhang Hongying , Benbatoul Khalid D. , Folger Peter , Sheng Xia , Tsai Cheng-Yu , Howell Stephen B. , Rice William G.
Published: April 2023

Differential expression genes from RNA-seq and RPPA.
Figure S7 PIP3 treatment does not affect mitotic progression in nontransformed cells. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a and b) The hTERT-RPE1 cells and HUVEC cells were synchronized, PIP3 treated, and analyzed as in Figure 4a and 4b. Plk1 inhibition efficiency examined by western blotting was shown in the top. (c and d) Percentages of mitotic cells at different phases were quantified in these treated cells (n.s, not significant; n=3). (e) Time-lapse microscopy of nontransformed cells with or without PIP3 treatment. hTERT-RPE1 cells and HUVEC cells stably expressing histone H2B-RFP were treated with 0.1% DMSO or 20 μM of PIP3 for 72 h and analyzed by time-lapse imaging. (f and g) The duration of total mitosis (f) and time spent in each sub-stage of mitosis (g) were further quantified (n.s, not significant; n{greater than or equal to}25).
Figure S6 Correlation between Plk1 expression level and PIP3 sensitivity. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a and b) Plk1 mRNA levels (a) and Plk1 protein levels (b) in various cell lines. (c-e) Pearson correlation co-efficiency was calculated between Plk1 mRNA level, Plk1 protein expression level, and PIP3 sensitivity (represented by IC50 value).
Figure S4 Cellular uptake and nuclear localization of PIPs. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Hela cells or A549 cells stably expressing histone H2B-RFP were incubated with 10 μM of different PIPs for 24 h. Cells were then subjected to live-imaging using confocal microscopy. Scale bar, 10 μm.
Supplementary Materials and Methods from Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma
Authors: Trautmann Marcel , Cyra Magdalene , Isfort Ilka , Jeiler Birte , Krüger Arne , Grünewald Inga , Steinestel Konrad , Altvater Bianca , Rossig Claudia , Hafner Susanne , Simmet Thomas , Becker Jessica , Åman Pierre , Wardelmann Eva , Huss Sebastian , Hartmann Wolfgang
Published: April 2023

Supplementary Materials and Methods: (Flow cytometry, Apoptosis assay, RNA interference and Statistical analysis)
Figure S2 PIP3 but not Hoechst 33258 shows Plk1 suppression ability. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a) Comparison of the cellular uptake of PIP3 and Hoechst 33258. Hela cells were incubated with different concentrations of PIP3 or Hoechst 33258 for 24 hours. Fluorescent microscopy images were acquired and as shown. (b) PIP3 but not Hoechst 33258 shows Plk1 suppression ability. Hela cells were treated with different concentrations of PIP3 or Hoechst 33258 for 72 hours and then collected for western blotting analysis to examine the Plk1 expression. (c) Evaluation of PIP3 stability in vitro. Hela cells were treated with 10 μM PIP3 for 72 hours, then cells were collected and lysed. Released PIP3 was monitored by RP-HPLC analysis. PIP3 dissolved in water was served as control.
Table S1 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

Measuring binding kinetics of human and mouse PD-1/PD-L1 interactions using surface plasmon resonance.
Supplementary Figure Legends from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

Supplementary Figure Legends
SUPPLEMENTARY MATERIALS AND METHODS from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

SUPPLEMENTARY MATERIALS AND METHODS
Figure S5 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

REGN2810 binds to PD-1 on T cells in tumor-bearing human PD-1 knock-in mice.
Supplementary Figures S1-S7 from A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Authors: Iwata Tomomi Nakayama , Ishii Chiaki , Ishida Saori , Ogitani Yusuke , Wada Teiji , Agatsuma Toshinori
Published: April 2023

Supplementary Figure S1. The chemical structure of DS-8201a. Supplementary Figure S2. Importance of targeted delivery by the ADC. Supplementary Figure S3. Reduced antitumor effect of DS-8201a in an immunocompromised mouse model. Supplementary Figure S4. Cell growth inhibition activity of DS-8201a and DXd. Supplementary Figure S5. Increased CD8+ cell infiltration into tumors. Supplementary Figure S6. Reduced antitumor effect of DS-8201a by CD8 depletion. Supplementary Figure S7. DXd, the payload of DS-8201a directly increased expression of MHC class I.
Supplementary Figure S3 from Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo
Authors: Singh Krishna B. , Hahm Eun-Ryeong , Pore Subrata K. , Singh Shivendra V.
Published: April 2023

Correlation of SREBF1 (SREBP1) expression with that of key fatty acid synthesis genes in prostate tumors from TCGA (n=497).
Supplemental Methods and Figure Legends from Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
Authors: Wielgos Monica E. , Zhang Zhuo , Rajbhandari Rajani , Cooper Tiffiny S. , Zeng Ling , Forero Andres , Esteva Francisco J. , Osborne C. Kent , Schiff Rachel , LoBuglio Albert F. , Nozell Susan E. , Yang Eddy S.
Published: April 2023

Supplemental Methods and Figure Legends
Supplemental Figure 3 from Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
Authors: Patwardhan Parag P. , Musi Elgilda , Schwartz Gary K.
Published: April 2023

Migration Assay after nintedanib treatment
Figure S1 from Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Schwarz Roderich E.
Published: April 2023

Mouse body weight in MKN-45 (A) and SNU-5 (B) GAC cell-derived subcutaneous xenografts. NOD/SCID mice were subcutaneously injected with GAC cells. Mouse body weight was measured and presented as a bar chart during the therapy period.
Supplemental Figure 4 from STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
Authors: Njatcha Christian , Farooqui Mariya , Kornberg Adam , Johnson Daniel E. , Grandis Jennifer R. , Siegfried Jill M.
Published: April 2023

Short-term CS3D treatment decreases Ki-67 expression
Figure S3 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Metabolic stability of EC-70124
Supplementary Table SI from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Sequences of PCR primers.
Supplementary Table S1-S6 from Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Authors: Harada Takeshi , Matsumoto Shinji , Hirota Suguru , Kimura Hirokazu , Fujii Shinsuke , Kasahara Yuuya , Gon Hidetoshi , Yoshida Toshihiko , Itoh Tomoo , Haraguchi Naotsugu , Mizushima Tsunekazu , Noda Takehiro , Eguchi Hidetoshi , Nojima Satoshi , Morii Eiichi , Fukumoto Takumi , Obika Satoshi , Kikuchi Akira
Published: April 2023

The sequences of ARL4C ASOs (Table S1), primers (Table S2) and siRNA (Table S3). Relationship between ARL4C expression and clinicopathological facrors of HCC and CRC cases (Table S4). Univariate analysis of relapse-free survival of HCC and CRC (Table S5). mRNA levels of candidate off-target genes for ARL4C ASO (Table S6).
Figure S5 from Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Authors: Harada Takeshi , Matsumoto Shinji , Hirota Suguru , Kimura Hirokazu , Fujii Shinsuke , Kasahara Yuuya , Gon Hidetoshi , Yoshida Toshihiko , Itoh Tomoo , Haraguchi Naotsugu , Mizushima Tsunekazu , Noda Takehiro , Eguchi Hidetoshi , Nojima Satoshi , Morii Eiichi , Fukumoto Takumi , Obika Satoshi , Kikuchi Akira
Published: April 2023

Fluorescence imaging confirms delivery of ASO into liver in tumor-free mouse.
Figure S4 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

HER3 expression and activation status in colorectal cell lines
Table S2 from Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer
Authors: Hsu Hung-Chih , Lapke Nina , Wang Chuang-Wei , Lin Pei-Yi , You Jeng Fu , Yeh Chien Yuh , Tsai Wen-Sy , Hung Hsin Yuan , Chiang Sum-Fu , Chen Hua-Chien , Chen Shu-Jen , Hsu An , Yang Tsai Sheng
Published: April 2023

List of tumor and plasma variants and their ctDNA detection thresholds
Figure S1 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

Structure of U3-1402
Supplementary Materials from Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR
Authors: Borgatti Antonella , Koopmeiners Joseph S. , Sarver Aaron L. , Winter Amber L. , Stuebner Kathleen , Todhunter Deborah , Rizzardi Anthony E. , Henriksen Jonathan C. , Schmechel Stephen , Forster Colleen L. , Kim Jong-Hyuk , Froelich Jerry , Walz Jillian , Henson Michael S. , Breen Matthew , Lindblad-Toh Kerstin , Oh Felix , Pilbeam Kristy , Modiano Jaime F. , Vallera Daniel A.
Published: April 2023

Detailed Methods for Immunohistochemistry Detailed Description of the Canine Clinical Study eBAT Pharmacokinetics and Neutralizing Antibody Assays Supplementary Table 1. Correlation between patient covariates and death Supplementary Table 2: Patient information (TMA) Supplementary Table 3: Cox regression analysis for time-to-progression Supplementary Figure 1. Survival probability based on EGFR Supplementary Figure 2. Quantification of EGFR and uPAR expression in normal canine tissues and in canine hemangiosarcoma Supplementary Figure 3. CONSORT diagram for SRCBST study
Figures S1-S7 from CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma
Authors: Maity Gargi , Ghosh Arnab , Gupta Vijayalaxmi , Haque Inamul , Sarkar Sandipto , Das Amlan , Dhar Kakali , Bhavanasi Sneha , Gunewardena Sumedha S. , Von Hoff Daniel D. , Mallik Sanku , Kambhampati Suman , Banerjee Sushanta K. , Banerjee Snigdha
Published: April 2023

Fig. S1. Detection of cross-reactivity of Cyr61 and CTGF antibodies; Fig. S2. CYR61 ablation in AsPC-1 Cell Line using CRISPR/Cas9 Gene Editing; Fig. S3. Knockdown of CYR61 in Panc-1 cells and AsPC-1 cells using stable transfection of shRNA and CRISPR/Cas9 Gene Editing techniques, respectively; Fig. S4. CYR61 status in sub-populations (SP and NSP) in Panc-1 cells; Fig. S5. CYR61 suppresses the effect of Gemcitabine (GEM) on sphere-forming ability of Panc-1 cells; Fig. S6. Time-dependent effect of gemcitabine (GEM) on cell viability of three different PDAC cell lines; Fig. S7. Effect of hrCYR61/CCN1 on ð�›,-SMA expression in HPaSteC cells
Figure S5 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

The direct sequencing for junction of JHDM1D and BRAF.
Figure S3 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Authors: Min Ahrum , Jang Hyemin , Kim Seongyeong , Lee Kyung-Hun , Kim Debora Keunyoung , Suh Koung Jin , Yang Yaewon , Elvin Paul , O'Connor Mark J. , Im Seock-Ah
Published: April 2023

AZD3514 enhanced the anti-tumor effect of olaparib by down-regulating DDR activation in MCF7 cells
Figure S4 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

Comparative genomic hybridization assay of SNU-16 parental cell and AZD-R clones.
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Authors: Tomita Yusuke , Kurozumi Kazuhiko , Yoo Ji Young , Fujii Kentaro , Ichikawa Tomotsugu , Matsumoto Yuji , Uneda Atsuhito , Hattori Yasuhiko , Shimizu Toshihiko , Otani Yoshihiro , Oka Tetsuo , Kaur Balveen , Date Isao
Published: April 2023

Supplementary Figure 3 shows Full scans of the western blotting shown in the figure 6.
Table S1 from HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
Authors: Proia David A. , Smith Donald L. , Zhang Junyi , Jimenez John-Paul , Sang Jim , Ogawa Luisa Shin , Sequeira Manuel , Acquaviva Jaime , He Suqin , Zhang Chaohua , Khazak Vladimir , Astsaturov Igor , Inoue Takayo , Tatsuta Noriaki , Osman Sami , Bates Richard C. , Chimmanamada Dinesh , Ying Weiwen
Published: April 2023

Cross-species plasma stability of STA-12-8666 as a function of time
Table S2 from Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
Authors: Berndt-Paetz Mandy , Schulze Philipp , Stenglein Philipp C. , Weimann Annett , Wang Qiang , Horn Lars-Christian , Riyad Yasser M. , Griebel Jan , Hermann Ralf , Glasow Annegret , Stolzenburg Jens-Uwe , Neuhaus Jochen
Published: April 2023

Table S2 shows raw data of microscopic tumor evaluation.
Figure S1 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

FG129 binding to cancer cell lines, but not PBMC or HUVEC
Supplemental Figure 3 from Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Beggs Reena R. , Cooper Tiffiny S. , Weaver Alice N. , Yang Eddy S.
Published: April 2023

Supplemental Figure S3. In vivo toxicity data
Supplementary Figure S2. ADC PK profiles from Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Pires Thomas A. , Setter Jocelyn R. , Hunter Joshua H. , Cochran Julia H. , Waight Andrew B. , Gordon Kristine A. , Toki Brian E. , Emmerton Kim K. , Zeng Weiping , Stone Ivan J. , Senter Peter D. , Lyon Robert P. , Jeffrey Scott C.
Published: April 2023

Pharmacokinetic profile of clearance for three ADCs.
Supplemental Materials and Methods from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Supplemental Materials and Methods
Suplemental Table S1 from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Supplemental Table S1. A list of antibodies, primers and siRNAs that were used and their manufacturers.
Supplementary Figure 7 from 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers
Authors: Jones Dylan T. , Valli Alessandro , Haider Syed , Zhang Qifeng , Smethurst Elizabeth A. , Schug Zachary T. , Peck Barrie , Aboagye Eric O. , Critchlow Susan E. , Schulze Almut , Gottlieb Eyal , Wakelam Michael J.O. , Harris Adrian L.
Published: April 2023

Significant differential abundance analysis of lipids as a heat map. A. MDA-MB-468 and B. PC3 spheroids were treated for 4 days with inhibitors against metabolic enzymes PDHK, ACC, FASN and DGAT, and kinases PI3K, AKT and mTOR at two different concentrations. All Lipids were compared against DMSO control, normalised to viable cells. Only lipids that were differentially abundant (p<0.05) following treatment by at least one drug (see dots in heat map) are epresented. Side covariates indicate lipid families, and lipids within each family are sorted by name. Paired t-test was used where 3 replicat es were available. Only fold change is reported where 2 samples were available. (p<0.05 and absolute log2FC>1).
Supplementary Figure S3 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Presents the goodness of fit plots when fitting a 1-compartmental model to the short term PK data.
Table S2 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Authors: Miller Michael L. , Fishkin Nathan E. , Li Wei , Whiteman Kathleen R. , Kovtun Yelena , Reid Emily E. , Archer Katie E. , Maloney Erin K. , Audette Charlene A. , Mayo Michele F. , Wilhelm Alan , Modafferi Holly A. , Singh Rajeeva , Pinkas Jan , Goldmacher Victor , Lambert John M. , Chari Ravi V.J.
Published: April 2023

Comparative in vitro potency of IGNs with a diimine (1), monoimine (3), and diamine (2) towards hematologic and solid tumor cell lines
Supplementary Figure 2 from Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Authors: Chang Chien-Hsing , Wang Yang , Zalath Maria , Liu Donglin , Cardillo Thomas M. , Goldenberg David M.
Published: April 2023

Molecular Structure of IMMU-132
Supplementary Figure S5. HB-EGF was selectively decreased in GSR (pool) cells with RIP2 siRNA. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

mRNA expression levels of the indicated genes were measured by quantitative RT-PCR in MV522 cells and in GSR (Pool) cells upon treatment with control siRNA (siRNA control) or RIP2 siRNA (siRIP2).
Supplementary Figure S3. Treatment of EGFR ligands in BRAF V600E mutnat A375 melanoma cell line. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

A, A375 cells were treated with 100 nM GSK2118436 in the absence or presence of each ligand. Cellular lysates were probed with the indicated antibodies in western blots. B, In MTT assays, A375 cells were treated in control or with 20 nM GSK2118436 after treatment with each ligand. Data are normalized to GSK2118436 or control and are displayed as mean {plus minus} SEM (n = 3, ***P < 0.001).
Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Authors: Wengner Antje M. , Siemeister Gerhard , Koppitz Marcus , Schulze Volker , Kosemund Dirk , Klar Ulrich , Stoeckigt Detlef , Neuhaus Roland , Lienau Philip , Bader Benjamin , Prechtl Stefan , Raschke Marian , Frisk Anna-Lena , von Ahsen Oliver , Michels Martin , Kreft Bertolt , von Nussbaum Franz , Brands Michael , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

Effect of BAY 1217389 in monotherapy and combination therapy with paclitaxel on total KNL1 in A2780Cis tumors in nude mice
Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Authors: Wengner Antje M. , Siemeister Gerhard , Koppitz Marcus , Schulze Volker , Kosemund Dirk , Klar Ulrich , Stoeckigt Detlef , Neuhaus Roland , Lienau Philip , Bader Benjamin , Prechtl Stefan , Raschke Marian , Frisk Anna-Lena , von Ahsen Oliver , Michels Martin , Kreft Bertolt , von Nussbaum Franz , Brands Michael , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

Multinuclearity in U2OS cells induced by Mps1 inhibition